The recent breakout of Moderna reminded investors that AI stocks aren't the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely.
We ran an ***** ysis based on Insider Monkey's proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding at the end of the second quarter.
A total of 23 billionaire-led funds held stakes in Viatris (NASDAQ: VTRS) at the end of the second quarter, down slightly from 24 funds in the first quarter. The stock trades around $16 as of Sept. 1.
BioCryst (NASDAQ: BCRX) had 22 billionaire-led funds holding stakes at the end of the second quarter, up from 20 funds in the first quarter. The stock trades near $10 as of the start of September.
In this article, we will focus on VTRS. The stock is up about 33% so far this year.
#quarter #stocks #billionaire #vtrs
We ran an ***** ysis based on Insider Monkey's proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding at the end of the second quarter.
A total of 23 billionaire-led funds held stakes in Viatris (NASDAQ: VTRS) at the end of the second quarter, down slightly from 24 funds in the first quarter. The stock trades around $16 as of Sept. 1.
BioCryst (NASDAQ: BCRX) had 22 billionaire-led funds holding stakes at the end of the second quarter, up from 20 funds in the first quarter. The stock trades near $10 as of the start of September.
In this article, we will focus on VTRS. The stock is up about 33% so far this year.
#quarter #stocks #billionaire #vtrs
1 day ago
